Atossa Therapeutics, Inc.
ATOS
Rank in Stocks
#26257
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Share Price
$2.13
Last synced: 2026-11-09
Market Cap
$21.26M
Change (1 day)
0.47%
Change (1 year)
-82.54%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atossa Therapeutics, Inc. (ATOS)
Category
Healthcare
EPS for Atossa Therapeutics, Inc. (ATOS)
EPS as of June 2026 TTM: $-4.34
According to Atossa Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-4.34. At the end of 2025 the company had an EPS of $-4.04, a decrease compared to its 2024 EPS of $-3.00.
EPS history for Atossa Therapeutics, Inc. from 2009 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.34 | 7.43% |
| 2025 | $-4.04 | 34.67% |
| 2024 | $-3.00 | -16.67% |
| 2023 | $-3.60 | 14.29% |
| 2022 | $-3.15 | 16.67% |
| 2021 | $-2.70 | -90.86% |
| 2020 | $-29.55 | -2.96% |
| 2019 | $-30.45 | -63.09% |
| 2018 | $-82.50 | -49.86% |
| 2017 | $-164.55 | -57.69% |
| 2016 | $-388.95 | -72.86% |
| 2015 | $-1.43K | -12.96% |
| 2014 | $-1.65K | -12.45% |
| 2013 | $-1.88K | 70.73% |
| 2012 | $-1.10K | 8.05% |
| 2011 | $-1.02K | 106.19% |
| 2010 | $-494.40 | 1,261.98% |
| 2009 | $-36.30 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -460.83% |
US
|
|
| $-7.07 | 62.90% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| $12.88 | -396.78% |
BE
|
|
| $21.56 | -596.77% |
NL
|
Questions about Atossa Therapeutics, Inc.'s earnings per share (EPS)
What is Atossa Therapeutics, Inc.'s earnings per share (EPS)?
Atossa Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-4.34, as of Jun 2026.
What was Atossa Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Atossa Therapeutics, Inc.'s earnings per share (EPS) was $-4.04, compared with $-3.00 in 2024.
How has Atossa Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Atossa Therapeutics, Inc.'s earnings per share (EPS) was highest in 2021 ($-2.70) and lowest in 2020 ($-29.55).
How does Atossa Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Atossa Therapeutics, Inc.'s earnings per share (EPS) ($-4.34) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.